Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 39 min ago
Peer-reviewedCC BY-NC-ND 4.0eClinicalMedicine

Targeting the PI3K/AKT/mTOR pathway in endocrine-resistant, hormone receptor-positive, HER2-negative, advanced breast cancer

Related

  1. Real-world feasibility of first-line palbociclib for hormone receptor-positive HER2-negative locally advanced/metastatic breast cancer in women aged 70 years and older – final results of the endocrine-sensitive cohort in the French prospective non-interventional PalomAGE study
    E. Carola, P. Caillet, C. Falandry +19
    The BreastPeer-reviewedCC BY-NC-ND 4.0Full text1 citedGeneral biologyOncologyHAL
  2. BCAR4, BCAR3 and EGFR Display Different Degrees of Cross-Resistance to Endocrine Mono- and Combination Therapies in Hormone Receptor Positive, HER2 Negative Breast Cancer
    Zhangzan Huang, Noor Wortelboer, Corine M Beaufort +6
    Breast Cancer: Targets and TherapyPeer-reviewedCC BY-NCFull textOncologyDOAJEurope PMCPMC
  3. Gedatolisib for the treatment of hormone receptor-positive/HER2-negative advanced breast cancer: a European perspective
    Letizia Matera, Julian David Etessami, Carmine Valenza +1
    Future OncologyPeer-reviewedLicence not statedFull textOncologyPMC
  4. Endocrine therapy adherence and 10-year cardiometabolic risk in hormone receptor-positive breast cancer
    Jorge R Ledesma, Joshua Nugent, Richard Cheng +9
    JNCI Cancer SpectrumPeer-reviewedCC BY-NC-ND 4.0Full textOncologyPMC
  5. Primary Endocrine Therapy vs Upfront Surgery for Older Women With Estrogen Receptor–Positive Breast Cancer
    Neil Carleton, Jian Zou, Yangyang Mu +6
    JAMA Network OpenPeer-reviewedCC BY-NC-ND 4.0Full textOncologyCrossrefPMC
BibTeX
@article{glaviano2026targeting,
  title = {{Targeting the PI3K/AKT/mTOR pathway in endocrine-resistant, hormone receptor-positive, HER2-negative, advanced breast cancer}},
  author = {Antonino Glaviano and Rachel O. Abelman and Andreas Varkaris and Samika Varma and Kelly E. McCann and Alan Prem Kumar and Patrizia Diana and Robertus A.M. de Bruin and Dejan Juric and Neil Vasan and Seth A. Wander},
  journal = {eClinicalMedicine},
  year = {2026},
  month = nov,
  doi = {10.1016/j.eclinm.2026.104320},
  url = {https://linkinghub.elsevier.com/retrieve/pii/S2589537026005730},
  note = {CC BY-NC-ND 4.0},
}
RIS
TY  - JOUR
TI  - Targeting the PI3K/AKT/mTOR pathway in endocrine-resistant, hormone receptor-positive, HER2-negative, advanced breast cancer
AU  - Antonino Glaviano
AU  - Rachel O. Abelman
AU  - Andreas Varkaris
AU  - Samika Varma
AU  - Kelly E. McCann
AU  - Alan Prem Kumar
AU  - Patrizia Diana
AU  - Robertus A.M. de Bruin
AU  - Dejan Juric
AU  - Neil Vasan
AU  - Seth A. Wander
PY  - 2026
DA  - 2026/11/01
JO  - eClinicalMedicine
DO  - 10.1016/j.eclinm.2026.104320
UR  - https://linkinghub.elsevier.com/retrieve/pii/S2589537026005730
SN  - 2589-5370
ER  -